SBBP Strongbridge Biopharma plc

+0  (4%)
Previous Close 4.20
Open 4.15
Price To book 2.22
Market Cap 153.71M
Shares 35,335,000
Volume 10,424
Short Ratio 1.24
Av. Daily Volume 93,721

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 enrollment from second trial to begin mid-2017 with top-line data expected in 3Q 2018.
COR-003 (levoketoconazole) - LOGICS
Endogenous Cushing’s syndrome
Phase 3 top-line data due 1Q 2018.
COR-003 (levoketoconazole) - SONICS
Endogenous Cushing’s syndrome